Brokerages Set Spero Therapeutics (SPRO) Price Target at $27.67

Spero Therapeutics (NASDAQ:SPRO) has been assigned a consensus rating of “Hold” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $27.67.

SPRO has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, January 30th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Thursday, January 11th. Cantor Fitzgerald set a $27.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 12th. Finally, ValuEngine upgraded shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

How to Become a New Pot Stock Millionaire

Shares of SPRO stock traded down $0.25 during trading hours on Wednesday, hitting $12.91. The company’s stock had a trading volume of 30,735 shares, compared to its average volume of 39,614. The company has a market capitalization of $189.10 and a P/E ratio of -0.72. Spero Therapeutics has a 12-month low of $9.66 and a 12-month high of $19.00.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Monday, April 2nd. The company reported ($1.59) EPS for the quarter, beating the consensus estimate of ($1.77) by $0.18. The business had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $0.40 million. equities analysts forecast that Spero Therapeutics will post -4.44 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. California Public Employees Retirement System acquired a new position in shares of Spero Therapeutics in the 4th quarter valued at $294,000. Atlas Venture Associates IX LLC acquired a new position in Spero Therapeutics during the fourth quarter worth $16,179,000. BVF Inc. IL acquired a new position in Spero Therapeutics during the fourth quarter worth $12,093,000. Rock Springs Capital Management LP acquired a new position in Spero Therapeutics during the fourth quarter worth $6,169,000. Finally, AWM Investment Company Inc. acquired a new position in Spero Therapeutics during the fourth quarter worth $4,112,000. Hedge funds and other institutional investors own 46.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://weekherald.com/2018/04/21/brokerages-set-spero-therapeutics-spro-price-target-at-27-67.html.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply